February 13, 2024
LEI: 213800RG7JNX7K8F7525
Life Science REIT plc
("Life Science REIT"
or the "Company")
New Lease at Oxford Technology
Park
Building 5 let to WAE Technologies
Limited
Life Science REIT (LSE: LABS), the real estate
investment trust focused on UK life sciences properties, is pleased
to announce that it has fully let Building 5 at Oxford Technology
Park ("OTP"), covering 57,000 sq. ft. to WAE Technologies Limited
("WAE Technologies"), a technology and engineering services
provider delivering innovative solutions to a range of sectors
including green energy, medical engineering and
automotive.
OTP is strategically located to provide
excellent access to the academic and research institutions in and
around Oxford University including the neighbouring Begbroke
Science Park. Its Hybrid Buildings are highly flexible, and can
provide any configuration of offices, labs, R&D and production
space, to suit the evolving needs of businesses in this sector.
Building 5 reached practical completion this week and is on track
to achieve a BREEAM Excellent certification.
WAE Technologies is part of Fortescue, a listed
Australian company which also has an investment fund, Foresight WAE
Technology Fund, which invests in a wide variety of businesses
including spinouts from Oxford and Cambridge Universities such as
Refeyn (molecular mass measurement) and ZOMP (3D whole-cell
imaging).
WAE Technologies will pay an annual rent of
£1,146,000, equating to £20.10 psf for a ten-year term, with a
break clause at year five on half the space and a rent review at
the end of the fifth year. The space has been fitted out as offices
and R&D space by the occupier.
Ian Harris,
Director of Asset Management at Ironstone Asset Management, the
Company's Investment Adviser, said: "OTP's
combination of flexible, affordable, and best in class space as
well as its proximity to leading, global life sciences institutions
is compelling for a wide range of occupiers. WAE will be the
largest occupier at OTP and its presence is a major step forward in
delivering a vibrant and collaborative community at
OTP."
OTP was acquired by Life Science REIT in May
2022. It now comprises six completed buildings totalling 230,500
sq. ft. and 266,100 sq. ft. of development space. Existing
occupiers at the park include The Native Antigen Company, a
developer and manufacturer of antigens and antibodies, Oxford Gene
Technology, a provider of clinical research and diagnostic
solutions and Oxford Ionics, a leading quantum computing
business.
END
Enquiries:
Ironstone Asset Management - Investment
Adviser
|
+44 20 3011 2160
|
Simon Farnsworth, Managing
Director
Simon.farnsworth@ironstoneam.com
|
|
Joanna Waddingham, Head of Investor
Relations and Corporate Affairs
|
|
Joanna.Waddingham@ironstoneam.com
|
|
|
|
Link Company Matters Limited - Company
Secretary
|
|
labs_cosec@linkgroup.co.uk
|
|
|
|
Panmure Gordon (UK) Limited - Joint Corporate
Broker
|
+44 20 7886 2500
|
Alex Collins / Tom
Scrivens
|
|
|
|
Jefferies International Limited - Joint Corporate
Broker
|
+44 20 7029 8000
|
Tom Yeadon / Oliver
Nott
|
|
G10
Capital Limited - AIFM
|
+44 20 7397 5450
|
Maria Baldwin
|
|
Buchanan - Financial PR
|
+44 20 7466 5000
|
Mark Court / Henry Wilson / Verity
Parker
|
|
LifeSciencereit@buchanan.uk.com
|
|
Notes to editors
Life Science REIT plc is a specialist
property business focused on the UK's growing life science sector.
The Company's portfolio of assets is located across the "Golden
Triangle" of research and development hubs in Oxford, Cambridge and
London's Knowledge Quarter and its strategic vision is to become
the property provider of choice for life science companies in the
UK.
Life Science REIT is addressing the
acute demand-supply imbalance for laboratory space in the "Golden
Triangle", which is characterised by low vacancy rates and prime
rental increases. The UK life science sector itself is benefiting
from a buoyant early stage funding environment, driving demand for
laboratory space.
The Company's diverse portfolio of
assets ranges from a 20-acre science park currently under
development through to fully let buildings, with an important part
of the Company's strategy being the conversion of existing
properties to laboratory space.
The Company's investment policy is
focused on capital growth whilst also providing a growing level of
income.
Life Science REIT trades on the Main
Market of the London Stock Exchange under the ticker
LABS.
Further information is available
at https://lifesciencereit.co.uk.
To sign up for email alerts, please visit https://lifesciencereit.co.uk/investors/.